- ResApp awarded second CE mark for its first smartphone-based diagnostic test for respiratory disease.- CE Mark certification indicates that ResAppDx-EU version 2 meets the essential requirements of all the applicable European regulations as a class IIa medical device and allows for its sale throughout the European Economic Area.- ResAppDx-EU version 2 is a software-only solution that runs on a smartphone and does not require any additional hardware or accessories.ResApp Health Ltd., the
Read More
ResApp
ResApp Awarded CE Mark for Smartphone-Based Diagnostic Test for Respiratory Disease
ResApp Health, the developers of the world’s first smartphone-based diagnostic test for respiratory disease where one simply coughs into the phone and the machine learning-based algorithm diagnoses the underlying respiratory disease, has received CE Mark certification as a Class IIa medical device.Significance of CE Mark CertificationCE Mark certification indicates that ResAppDx-EU meets the essential requirements of all the applicable European regulations as a medical device and allows for the
Read More
ResApp Develops Sound-based Algorithm to Diagnose Sleep Apnea via Smartphone
ResApp Health, the Australian digital health startup that has been working on software for smartphones that can diagnose respiratory diseases from the sound signatures of coughs (US clinical trials underway), has announced a new area of development – a diagnostic test to diagnose obstructive sleep apnea (OSA) using a smartphone – simply by leaving the smartphone next to one’s bed to record sounds of the subject while sleeping – and then the algorithms provide a diagnosis (similar AI use to the
Read More
ResApp Licenses New Algorithm to Improve Diagnostic Screening for Childhood Pneumonia
ResApp Health Limited, a digital health startup provider of smartphone apps for respiratory disease diagnosis and management has signed a licensing agreement with UniQuest, the main commercialization company of The University of Queensland. The licensing agreement includes an additional diagnostic toolset of machine-learning algorithms that use a combination of clinical features to screen for childhood pneumonia. Pneumonia is the leading cause of mortality for children below five years of age.
Read More
ResApp Expands Research Collaboration With Mass General for Diagnostic App
ResApp, a Australian-based digital health startup that has developed a smartphone app that can diagnose respiratory diseases based on the sound signatures of the coughs has entered into a two-year expanded research collaboration with Massachusetts General Hospital (MGH). As part of the research collaboration, ResApp and MGH will perform additional analysis of the SMARTCOUGH-C study data, use the SMARTCOUGH-C dataset to investigate the state of respiratory disease clinical practice today and
Read More
ResApp Nabs $12.5M For Smartphone App That Instantly Diagnose Respiratory Diseases
ResApp, a Australian-based digital health startup that has developed a smartphone app that can diagnose respiratory diseases based on the sound signatures of the coughs, announced it has raised $12.5 million in funding. The oversubscribed round was led by Jett Capital Advisors, Empire Capital Partners and CPS Capital Group. The company plans to use the funding to accelerate the FDA approval for its adult diagnostic test and expand US market access beyond telehealth into in-clinic use, including
Read More
